1. Home
  2. CCM vs HIND Comparison

CCM vs HIND Comparison

Compare CCM & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$4.78

Market Cap

14.9M

Sector

Health Care

ML Signal

N/A

HIND

Vyome Holdings Inc.

HOLD

Current Price

$2.14

Market Cap

13.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
HIND
Founded
1997
2017
Country
China
United States
Employees
N/A
18
Industry
Medical/Nursing Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.8M
IPO Year
2009
2016

Fundamental Metrics

Financial Performance
Metric
CCM
HIND
Price
$4.78
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
30.7K
22.7K
Earning Date
05-12-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$1.75
52 Week High
$10.77
$12.87

Technical Indicators

Market Signals
Indicator
CCM
HIND
Relative Strength Index (RSI) 53.15 52.65
Support Level $3.57 $1.99
Resistance Level $5.71 $2.36
Average True Range (ATR) 0.72 0.15
MACD -0.03 0.01
Stochastic Oscillator 30.74 67.36

Price Performance

Historical Comparison
CCM
HIND

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: